DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening and Drug Repositioning Resource

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) contains 2,320 bioactive compounds, each with clinical approval from the FDA or equivalent regulatory agencies, and is validated for high-throughput and high-content screening (HTS/HCS) applications (APExBIO product page). The library is formulated in 10 mM DMSO solutions for standardized screening workflows, with stability of 12 months at -20°C and up to 24 months at -80°C. It supports drug repositioning, pharmacological target identification, and pathway analysis, with documented utility in cancer drug discovery and neurodegenerative disease models (He et al., 2023). Representative compounds include doxorubicin, metformin, and atorvastatin, reflecting a diversity of mechanisms such as receptor modulation and enzyme inhibition.

Biological Rationale

Drug repositioning accelerates therapeutic discovery by identifying new uses for approved drugs (He et al., 2023). High-throughput screening (HTS) of FDA-approved compound libraries enables systematic evaluation of pharmacological effects across diverse disease models. Clinically validated compounds with known pharmacokinetics and safety profiles minimize translational barriers. Libraries such as the DiscoveryProbe™ FDA-approved Drug Library are essential for rapid identification of novel modulators of disease-relevant targets, including signaling pathways and protein-protein interactions. Approved compound collections are particularly valuable in oncology, neurodegeneration, and infectious diseases, where mechanism-based screening can reveal unexpected therapeutic opportunities (internal link; this article extends prior work by benchmarking recent screening results and regulatory details).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library comprises molecules with well-characterized mechanisms, including:

• Receptor agonists and antagonists: Modulate signaling pathways by activating or inhibiting cell surface and nuclear receptors.
• Enzyme inhibitors: Block catalytic activity of enzymes such as kinases, proteases, or metabolic enzymes (e.g., metformin).
• Ion channel modulators: Alter membrane potential and cellular excitability, relevant in neurological disease research.
• Signal pathway regulators: Influence intracellular cascades (e.g., MAPK, PI3K/Akt) critical for cell survival and apoptosis.

Representative compounds include doxorubicin (topoisomerase inhibitor), atorvastatin (HMG-CoA reductase inhibitor), and terfenadine (histamine receptor antagonist). This mechanistic diversity supports broad applicability in disease model screening and target validation. Mechanism-specific screening enables the rapid identification of compounds with desired biological effects, as exemplified by BRET-based assays for disrupting 14-3-3:BAD interactions in cancer research (He et al., 2023).

Evidence & Benchmarks

• The library contains 2,320 compounds, each approved by the FDA, EMA, HMA, CFDA, or PMDA, or listed in recognized pharmacopeias (product page).
• High-throughput screening using a subset of 1,971 FDA-approved drugs enabled identification of three compounds (terfenadine, penfluridol, lomitapide) capable of disrupting 14-3-3 protein:BAD interactions and inducing apoptosis in colorectal cancer cells (He et al., 2023, DOI).
• Compounds are pre-dissolved at 10 mM in DMSO, supplied in 96-well microplates, deep well plates, or 2D-barcoded screw-top vials for flexible integration (APExBIO).
• Formulations are stable for 12 months at -20°C and up to 24 months at -80°C, supporting long-term screening campaigns (see internal link; this article updates stability claims with recent vendor data).
• Validated in high-content screening (HCS) for neurodegenerative and oncology targets, enabling reproducible target identification and pathway mapping (internal link; this review extends the mechanistic context).
• The primary screening approach using the library achieved a Z’-score of 0.52, indicating robust assay quality (He et al., 2023, DOI).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library facilitates applications in:

• Cancer research drug screening: Rapid identification of pro-apoptotic agents for colorectal and other cancers.
• Neurodegenerative disease drug discovery: Screening for modulators of neuronal survival and function.
• Drug repositioning screening: Efficient exploration of new indications for known drugs.
• Pharmacological target identification: Systematic mapping of compound-target interactions.
• Signal pathway regulation and enzyme inhibitor screening: Mechanistic studies in cell-based and biochemical assays.

For a broader discussion of translational research impacts, see Rewiring Translational Research (this article clarifies the specific contribution of FDA-approved libraries in mechanistic pathway studies).

Common Pitfalls or Misconceptions

• Not all compounds are equally bioavailable in all model systems; in vitro hits require pharmacokinetic validation in vivo.
• The library supports screening for small-molecule drugs only; biologics and peptide therapeutics are not included.
• Assay results depend on compound solubility and stability; DMSO concentration and storage conditions must be controlled.
• FDA approval does not guarantee efficacy or safety for new indications; repositioned drugs require full clinical validation.
• Some compounds may have off-target effects not captured in initial screens; orthogonal validation is recommended.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is compatible with standard HTS and HCS platforms. Compounds are delivered as 10 mM DMSO solutions in microplates or tubes suitable for robotic handling. Shipping options include blue ice or room temperature, depending on sample size and user preference. Storage at -20°C ensures 12-month stability; -80°C extends stability to 24 months. Assay miniaturization is supported by 96-well and deep well formats. 2D barcoded vials enable traceability and automation in large-scale screens. The library’s chemical diversity covers a broad spectrum of targets, supporting diverse research objectives from oncology to infectious disease. For additional integration guidance, see Accelerating Drug Repurposing (this article provides updated workflow best practices and parameterization).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO offers a rigorously curated, stable, and versatile resource for high-throughput and high-content drug screening. Its regulatory-verified composition and format flexibility facilitate reproducible drug repositioning and target identification across oncology, neurodegeneration, and other biomedical domains. Ongoing benchmarking demonstrates the power of FDA-approved compound libraries to accelerate translational research and mechanistic discovery. Future advances will likely leverage this resource in combination with phenotypic screening, multi-omics, and AI-driven analysis for next-generation therapeutic discovery. For detailed product information and ordering, visit the DiscoveryProbe™ FDA-approved Drug Library (L1021) product page.